European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use immediately.

Pfizer PFE announced that it is voluntarily withdrawing all lots of its sickle-cell disease (SCD) medication Oxbryta (voxelotor) from all markets where the drug is approved. Why PFE is Withdrawing the Drug All of a Sudden?

The decision is based on the totality of clinical data, which now indicates that the benefit of Oxbryta no longer outweighs the risks associated with its use, Pfizer said. Pfizer said it will further review and investigate the available data and had notified regulatory authorities about its findings.